Despite recent advancements in surgery and genetics, Gliomas Grade 4 (GG4), including astrocytoma IDH-mutant grade 4 and the astrocytoma IDH wt, face a grim prognosis, marked by a high likelihood of early tumor recurrence (TR) after postoperative radio-chemotherapy [1]. Here, IDH2 is linked to central nervous system cancer.